Unither Bioélectronique Completes the World's First Successful Test Flight of a Piloted Hydrogen-Powered Helicopter

BROMONT, Québec, April 3, 2025: Unither Bioélectronique, Inc. (**UB**), a subsidiary of United Therapeutics Corporation (Nasdaq: **UTHR**), today announced that UB completed the first successful test flight of a piloted hydrogen-powered helicopter at its test and development facility located at Bromont Airport in Bromont, Quebec. This first test flight represents a critical step toward developing conforming designs and certification protocols for hydrogen-powered aircraft.

This historic flight represents several firsts for aviation:

- The world's first flight demonstration of a piloted hydrogen-powered helicopter;
- Canada's first piloted hydrogen-powered flight; and
- A successful validation of Proton Exchange Membrane (**PEM**) hydrogen fuel cell technology, proving its capability to support the demanding power requirements of a vertical take-off and landing (**VTOL**) powered lift profile.

The flight test took place on March 27, 2025 at Roland-Désourdy Airport in Bromont, Québec (ICAO code: CZBM), with UB's test pilot **Ric Webb** at the controls. The flight was conducted under an experimental flight permit issued by Transport Canada Civil Aviation (**TCCA**) for UB's experimental Robinson R44 Raven II with registration code C-FXUB. The three minute, 16 second test flight demonstrated the hover and maneuvering capabilities of the hydrogen powertrain.

Through this test flight, Unither Bioélectronique has successfully integrated a hybrid hydrogen fuel cell/electric battery powertrain system into a VTOL demonstrator. The system combines two low-temperature PEM fuel cell stacks with a small battery pack to manage transient power demands. Approximately 90% of the energy used for the flight was derived from the helicopter's hydrogen fuel cells.

The test flight was conducted as part of **Project Proticity**™, a collaboration between UB and Torrance, California-based **Robinson Helicopter** announced in August 2024. Project Proticity aims to accelerate the development of zero-emission helicopters based on Robinson's proven R44 and R66 helicopter models. Robinson provides its extensive engineering, technical, and regulatory expertise and UB integrates hydrogen technology and conducts testing for certification through TCCA and the U.S. Federal Aviation Administration.

"Our first test flight successfully demonstrated the hover and maneuver capabilities of our innovative hydrogen powertrain," said **Mikaël Cardinal**, Vice President, Program Management & Business Development, Organ Delivery Systems for Unither Bioélectronique. "Our next phase of development will focus on integrating a liquid hydrogen storage system which we believe is an essential technology for enabling our extended-range missions to deliver manufactured organ alternatives to patients in need."

"The importance of this milestone in aviation history cannot be overstated, said **David Smith**, President and CEO of Robinson Helicopter Company. "Project Proticity has taken an incredible first step forward in the path to long range, zero emission vertical flight. We are excited to continue developing this technology with our partners at Unither Bioélectronique."

The flight test was also a milestone for parent company United Therapeutics' commitment to sustainability in its operations. As part of the company's Revolutionary Wave of growth, United Therapeutics envisions delivering an unlimited supply of manufactured organ alternatives to patients using a vertically integrated logistics chain with a lower environmental impact than conventional transportation options.

"Just as protons from hydrogen atoms drive the mitochondrial powerplants in each of our bodies' cells, we look forward to using protons from green hydrogen to drive the membrane-based fuel cell powerplants in our Robinson R66 Organ Delivery Electric helicopters," said **Martine Rothblatt, Ph.D.**, Chairperson and Chief Executive Officer of United Therapeutics.

About Unither Bioélectronique

Unither Bioélectronique, Inc. (**UB**), a wholly owned subsidiary of United Therapeutics Corporation, is driving the innovation and development of autonomous, environmentally friendly, airborne organ delivery systems. UB intends to develop and operate a fleet of next-generation, electric- and hydrogen-powered, optionally piloted, and powered-lift aircraft with the capacity to take off and land vertically at hospitals – capable of quickly delivering manufactured organs for human transplant. UB plays a critical role in support of United Therapeutics' mission to address the unmet medical needs of patients with end-stage organ diseases. More information is available at unither.aero. Information specific to Project Proticity is available at proticity.aero.

About Robinson Helicopter Company

For more than 50 years, Robinson Helicopter Company has been at the forefront of the helicopter industry by delivering safety-enhancing technologies, including OEM-designed crash-resistant fuel cells, 4K cockpit video cameras, autopilot systems, and NVG-compatible cockpits. Robinson is committed to developing, manufacturing, and supporting the most reliable and efficient helicopters in the industry. For additional information, visit www.robinsonheli.com.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (**PBC**). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our plans to develop manufactured organs and a fleet of sustainable aircraft for delivery of manufactured organs, our expectation that our collaboration with Robinson Helicopter Company will enable us to accelerate development of hydrogen-powered aircraft and increase their prospects for regulatory approval, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in United Therapeutics Corporation's periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 3, 2025, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events or any other reason.

For Further Information Contact:

Dewey Steadman at (202) 919-4097 (media/investors)
Harry Silvers at (301) 578-1401 (investors)
https://ir.unither.com/contact-ir

PICTURES TO BE DISTRIBUTED FOR PUBLIC USE

Ric Webb of Unither Bioélectronique performs pre-flight checks in the company's experimental hydrogen-powered Robinson R-44 Raven II helicopter at Roland-Désourdy Airport in Bromont, Québec, March 27, 2025.
Photo credit: Peter Krieger via Press Record Media.

Mikael Cardinal, left, and test pilot Ric Webb, right, of Unither Bioélectronique celebrate after the company's successful first test flight of a hydrogen-powered Robinson R-44 Raven II helicopter at Roland-Désourdy Airport in Bromont, Québec, March 27, 2025.

Photo credit: Peter Krieger via Press Record Media.

Test pilot Ric Webb of Unither Bioélectronique performs a hover flight in the company's experimental hydrogen-powered Robinson R-44 Raven II helicopter at Roland-Désourdy Airport in Bromont, Québec, March 27, 2025.

Photo credit: Peter Krieger via Press Record Media.

Test pilot Ric Webb of Unither Bioélectronique performs a hover flight in the company's experimental hydrogen-powered Robinson R-44 Raven II helicopter at Roland-Désourdy Airport in Bromont, Québec, March 27, 2025.

Photo credit: Peter Krieger via Press Record Media.

The Unither Bioélectronique team celebrates after the company completed its first hover and maneuver flight milestone with an experimental hydrogen-powered Robinson R-44 Raven II helicopter at Roland-Désourdy Airport in Bromont, Québec, March 27, 2025.

Photo credit: Peter Krieger via Press Record Media.